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Abstract 
Background: Tafenoquine (TQ) and primaquine (PQ) are 8‑aminoquinolines (8‑AQ) with anti‑hypnozoite activity 
against vivax malaria. PQ is the only FDA‑approved medicine for preventing relapsing Plasmodium vivax infection 
and TQ is currently in phase 3 clinical trials for the same indication. Recent studies have provided evidence that 
cytochrome P450 (CYP) metabolism via CYP2D6 plays a role in PQ efficacy against P. vivax and have suggested that 
this effect may extend to other 8‑AQs, including TQ. Here, a retrospective pharmacogenetic (PGx) investigation was 
performed to assess the impact of CYP2D6 metabolism on TQ and PQ efficacy in the treatment of P. vivax in the 
DETECTIVE study (TAF112582), a recently completed, randomized, phase 2b dose‑ranging clinical trial. The impact 
of CYP2D6 on TQ pharmacokinetics (PK) was also investigated in TAF112582 TQ‑treated subjects and in vitro CYP 
metabolism of TQ was explored. A limitation of the current study is that TAF112582 was not designed to be well 
powered for PGx, thus our findings are based on TQ or PQ efficacy in CYP2D6 intermediate metabolizers (IM), as there 
were insufficient poor metabolizers (PM) to draw any conclusion on the impact of the PM phenotype on efficacy.
Methods: The impact of genetically‑predicted CYP2D6 reduced metabolism on relapse‑free efficacy six months 
post‑dosing of TQ or PQ, both administered in conjunction with chloroquine (CQ), was assessed using exact statisti‑
cal methods in 198 P. vivax‑infected study participants comparing IM to extensive metabolizers (EM). The influence of 
CYP2D6 metabolizer phenotypes on TQ PK was assessed comparing median TQ area under the curve (AUC). In vitro 
metabolism of TQ was investigated using recombinant, over‑expressed human CYP enzymes and human hepato‑
cytes. Metabolite identification experiments were performed using liquid chromatography‑mass spectrometry.
Results: Reduction of CYP2D6 activity was not associated with an increase in relapse‑rate in TQ‑treated subjects 
(p = 0.57). In contrast, and in accordance with recent literature, CYP2D6 IMs were more common (p = 0.05) in PQ‑
treated subjects who relapsed (50 %) than in subjects who remained relapse‑free (17 %). Further, CYP2D6 metabolizer 
phenotypes had no significant effect on TQ AUC, and only minimal metabolism of TQ could be detected in hepatic 
in vitro systems.
Conclusion: Together, these data provide preliminary evidence that in CYP2D6 IMs, TQ efficacy in P. vivax‑infected 
individuals is not diminished to the same extent as PQ. As there were no PMs in either the TQ or PQ treatment arms 
of TAF112582, no conclusions could be drawn on potential differences in PMs. These findings suggest that differential 
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Background
Globally, it is estimated that 132–391 million Plasmo-
dium vivax clinical infections occur each year [1]. In 
order to treat and potentially eradicate relapsing forms 
of malaria, such as P. vivax, drugs with anti-hypnozoite 
activity are required to kill the latent hypnozoite liver-
stage of the parasite. Currently, primaquine (PQ) is the 
only drug approved by the US Food and Drug Admin-
istration (FDA) for this indication since schizonticidal 
drugs such as chloroquine (CQ) do not have anti-relapse 
efficacy. PQ is a member of the 8-aminoquinoline (8-AQ) 
drug class, which also includes tafenoquine (TQ). TQ is 
a synthetic derivative of PQ and is currently in phase 3 
clinical development after showing a good efficacy and 
tolerability profile in a recent phase 2b dose-ranging 
study [2].
Recent research has highlighted a potential phar-
macogenetic (PGx) effect on the efficacy of PQ in indi-
viduals who are naturally deficient in cytochrome P450 
2D6 (CYP2D6) activity. In both mice and humans, this 
research has provided consistent evidence that metabolic 
activation of PQ by CYP2D6 is required for anti-hyp-
nozoite activity, possibly via a toxic metabolite [3–7]. A 
further study in mice suggested that this CYP2D6 liabil-
ity may extend to other members of the 8-AQ drug class, 
including TQ [8]. Most recently, Vuong et al. [9] reported 
higher TQ exposure [area under the curve (AUC)] in 
CYP2D knock-out mice compared to wild type and sug-
gested CYP2D6 could potentially affect TQ pharmacoki-
netics (PK) in humans.
CYP2D6 is a highly polymorphic drug-metabolizing 
enzyme involved in the biotransformation of numerous 
medicines and it is well known that genetic polymor-
phisms in the CYP2D6 gene influence exposure to many 
drugs and/or active metabolites and responses [10, 11]. 
Metabolizer phenotype can be predicted for CYP2D6 
alleles, although underlying metabolic differences 
between individuals with the same CYP2D6 genotype 
can make phenotype inference challenging [10–13]. If, 
as proposed by Marcsisin et al. [8], the CYP2D6 liability 
observed for PQ extends to other members of the 8-AQ 
drug class, the high degree of genetic polymorphism and 
considerable variability in the distribution of functional 
alleles across the world, would pose major obstacles to 
the development of pharmacogenetically guided treat-
ment strategies.
The aim of the current study was to determine whether 
clinical anti-relapse efficacy of TQ and PQ, as well as TQ 
PK, are impacted by reduced CYP2D6 activity using a 
retrospective PGx assessment in subjects from a rand-
omized clinical trial. A complimentary aim was to eluci-




Participants’ samples were from Part 1 of the seamless 
Ph2b/3 TAF112582 study, a multi-centred, double-blind, 
randomized, parallel-group, placebo-controlled study 
to evaluate the efficacy, safety and tolerability of TQ in 
subjects infected with P. vivax [2]. TAF112582 Part 1 
consisted of six treatment arms: CQ (600 mg days 1 and 
2, 300  mg  day 3) plus TQ and PQ placebos; CQ (doses 
as above) combined with single dose TQ 50, 100, 300 or 
600  mg plus PQ placebo; or CQ (doses as above) com-
bined with PQ 15 mg daily for 14 days plus TQ placebo. 
Protocol approval was obtained from each site’s ethics 
committee or institutional review board and prospective 
written informed consent was obtained for all subjects 
involved in this PGx study, which was funded by GlaxoS-
mithKline (GSK) and the Medicines for Malaria Venture 
(MMV).
Tafenoquine pharmacokinetics data
A population PK model was developed to characterize 
systemic TQ concentrations in TAF112582 Part 1 sub-
jects treated with TQ. Model-predicted individual post 
hoc clearance estimates were utilized to generate the 
individual exposure (AUC) values for the analyses [14].
CYP2D6 genotyping and phenotype inference
Venous blood was collected into an EDTA vacutainer 
for each of the subjects who consented to PGx research. 
Genomic DNA was extracted from peripheral blood 
using the Gentra Puregene kit on the Autopure LS (Qia-
gen, Valencia, CA, USA) by Quest Diagnostics (Valen-
cia, CA, USA or Heston, UK). CYP2D6 genotyping was 
performed by BioProcessing Solutions (Piscataway, NJ, 
USA) using the Affymetrix® DMET-Plus array (Santa 
Clara, CA, USA). All genotype calling and quality control 
was performed in accordance with the manufacturers’ 
protocols.
effects of CYP2D6 metabolism on TQ and PQ efficacy could be a differentiation factor between these 8‑AQs, but 
results remain to be confirmed prospectively in the ongoing phase 3 studies.
Keywords: Plasmodium vivax malaria, Tafenoquine, Primaquine, CYP2D6, Efficacy, Pharmacogenetics, 
Pharmacokinetics
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Genetically predicted CYP2D6 metabolizer status was 
determined from this array. The translation of genotype 
information into metabolizer phenotype is challeng-
ing given the range of activity possible for an allele [12] 
and many classification schemes have been proposed or 
used in practice [5, 7, 12]. Here, subjects were classified 
as (1) poor metabolizers (PM) if they carried two ‘null’ 
(no enzymatic function) alleles; (2) intermediate metabo-
lizers (IM) if they carried one null and one functionally 
deficient allele, two deficient alleles, or one null allele and 
one normal (wildtype function) allele; and, (3) extensive 
metabolizers (EM) if they carried two normal alleles or 
one normal allele and one deficient allele. In addition, the 
CYP2D6 ‘activity score’ (AS) [12], which translates geno-
type into a qualitative measure of enzyme activity, was 
explored in this study. Briefly, for each study subject, AS 
was determined by summing the per-allele scores; a null 
allele having a score of 0, a deficient allele a score of 0.5 
and a normal allele a score of 1. Thus, PMs could have an 
AS of 0, IMs an AS of 0.5 or 1 and EMs an AS of 1.5 or 
2.0.
Statistical analysis
TAF112582 showed poor efficacy for TQ50 and 
TQ100  mg treatment arms, while higher dose treat-
ment arms, TQ300 and TQ600  mg, showed good effi-
cacy [2]. Therefore, to facilitate interpretation of results, 
the TQ low dose (50 and 100 mg) and high dose (300 and 
600 mg) treatment arms were combined. An exact logis-
tic regression model adjusting for country of origin was 
used to assess the effect of inferred CYP2D6 metabolizer 
phenotype or AS on clinical outcome within treatment 
arm. Because only 1 PM was identified in the clinical 
study, only subjects with IM or EM phenotypes were 
included in the analysis. Given published data indicating 
an effect of CYP2D6 metabolism on PQ efficacy [3–7], a 
one-sided test was applied to test the one-sided alterna-
tive hypothesis that reduced metabolism increased the 
risk of relapse due to P. vivax infection 6  months post-
dosing. For the PK assessment, a post hoc analysis using 
a non-parametric method to compare median TQ AUC 
between IM and EM subjects was conducted separately 
in the TQ low dose (50 or 100 mg) and TQ high dose (300 
or 600  mg) groups. All analyses were conducted using 
SAS/STAT (SAS Systemv9.2, SAS Institute Inc, Cary, NC, 
USA).
Chemicals in isoenzyme and hepatocyte experiments
Tafenoquine was supplied by Chemical Development, 
GlaxoSmithKline Research and Development Ltd. (Ste-
venage, UK). Glucose-6-phosphate (G6P), glucose-
6-phosphate dehydrogenase (G6PD) and β-nicotinamide 
adenine dinucleotide phosphate (NADP) were obtained 
from Sigma Chemical Company (St Louis, USA). All 
other commercially obtained chemicals and solvents 
were of high-performance liquid chromatography 
(HPLC) or analytical grade.
Isoenzymes
Supersomes™, containing individually over-expressed 
human CYP enzymes, derived from baculovirus-infected 
insect cells, and control Supersomes™ (lacking any 
native human CYP activity) were obtained from BD Bio-
sciences, Woburn, MA, USA. The enzymes used in this 
study were: CYP1A2, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP3A4 (Lot# 72600, 76739, 73030, 71916, 
73755, and 70741, respectively). Supersomes™ expressing 
CYP2C8, CYP2C9, CYP2C19, and CYP3A4 co-expressed 
CYP reductase and cytochrome b5, while Supersomes™ 
expressing CYP1A2 and CYP2D6 co-expressed CYP 
reductase only. TQ was incubated at 5 and 10  μM with 
Supersomes™ (BD Gentest, Woburn, MA, USA), overex-
pressing individual cytochrome P450 enzymes 1A2, 2C8, 
2C9, 2C19, 2D6, or 3A4 at 300 pmol/ml P450, in phos-
phate buffer (50 mM, pH 7.4) at 37 °C in a shaking water 
bath. Following an equilibration period of 5 min at 37 °C, 
reactions were started by the addition of pre-warmed 
cofactor solution [a NADPH regenerating system con-
taining 1.7 mg of NADP, 7.8 mg of G6P, and six units of 
G6PD per ml of 2 % (w/v) sodium hydrogen carbonate]. 
Incubations were conducted under conditions which 
limited the exposure of samples to light. All incubations 
were terminated after 120  min by addition of a volume 
of acetonitrile equal to the incubation volume. Control 
incubations were also performed in the absence of Super-
somes™, in the absence of cofactor and in the absence of 
TQ. Samples were centrifuged (Eppendorf, Hauppauge, 
NY, USA; approximately 13,000g, 3 min, room tempera-
ture), and supernatants removed for analysis by ultra 
performance liquid chromatography-mass spectrometry 
(UPLC-MS).
Human hepatocyte relay method
The human hepatocyte relay method used was similar to 
that previously reported by Di et al. [15]. Pooled cryopre-
served human hepatocytes from 26 donors were obtained 
from Life Technologies (MA, USA). Following thaw-
ing (as per supplier guidance), hepatocytes were resus-
pended in Williams’ E medium (Sigma) supplemented 
with cell maintenance pack (Life Technologies). The cells 
were counted using the trypan blue exclusion method 
and 12-well hepatocyte plates containing 1 million cells/
ml were spiked with TQ at a final concentration of 5 
and 10 μM in a final incubation volume of 0.50 ml. The 
plates were incubated at 37 °C with 95 % oxygen/5 % car-
bon dioxide, 75 % relative humidity for 24 h on an orbital 
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shaker in an incubator. At 24 h the hepatocyte suspension 
in the incubation plate was centrifuged (13,000g, 3 min, 
room temperature); a total of 600  µl of the supernatant 
was transferred to a clean 12-well plate and stored at 
−80 °C until the next relay experiment. For the next relay 
experiment, the supernatant plates were pre-warmed to 
37 °C for approximately 20 min, and further hepatocytes 
(prepared as described previously) were added to the 
samples to yield a final cell density of 1 million cells/ml. 
The plates were incubated at 37 °C for 24 h and processed 
as described earlier. Six relays were undertaken to give 
a total incubation time of 6 days and samples were pro-
tected from light wherever possible. A drug-only control 
plate was run under the same conditions to investigate 
any non-metabolic drug breakdown. At the end of the 
six relay method period the entire hepatocyte suspension 
was collected and centrifuged (Eppendorf, Hauppauge, 
NY, USA) at 13,000g for 3 min at room temperature, and 
transferred to vials prior to UPLC-MS analysis.
Tafenoquine analysis and structural identification of drug 
related components
Analyses of reaction phenotyping samples for TQ-related 
components were carried out by UPLC-MS using a 
Waters Acquity UPLC connected to a Waters Synapt G2S 
mass spectrometer using an Acquity UPLC BEH C18 col-
umn (100 ×  2.1 mm, 1.7 µm; Waters Corporation, Mil-
ford, MA, USA). The mobile phase consisted of 50 mM 
ammonium acetate (native pH; solvent A) and acetoni-
trile (solvent B) at a flow rate of 0.3 ml/min. A gradient 
was used, starting at 5 % B then linear phase to 95 % B 
by 12  min, held for 1  min before returning to the ini-
tial conditions by 13.5  min with these conditions being 
maintained for an additional 1.5 min before subsequent 
injections. TQ ([M + H]+) was detected at m/z 464 using 
positive ion electrospray ionization. Drug-related com-
ponents were identified based on charged molecular ions, 
mass accuracy and their collision-induced dissociation 
fragmentation. Authentic standards, when available, were 
used to compare chromatographic retention times and 
fragmentation patterns. Supporting data from previous 
studies were also used in the assignment of structures 
(unpublished data on file within DMPK (Drug Metabo-
lism and Pharmacokinetics) Department, GSK).
Results
Among 329 subjects who comprised the intent-to-treat 
(ITT) population in TAF112582, 237 (72  %) provided 
written informed consent and a blood sample for PGx 
research; this included 136/136 (100 %) of subjects from 
Peru, 98/99 (99 %) from Thailand, 3/57 (5 %) from India 
and 0/37 (0  %) from Brazil. Genetic data on 224 of the 
237 (95  %) subjects passed standard manufacturer data 
quality control. Among these 224 subjects, 20 subjects 
were excluded from analysis as they were either lost to 
follow-up or treated with non-study medications with 
potential anti-malarial properties. In a further five sub-
jects, metabolizer phenotype could not be unambigu-
ously determined from CYP2D6 genotypes, leaving a 
PGx analysis sample of 199 subjects. The distribution of 
these 199 subjects by treatment, country of origin and 
clinical outcome is shown in Table 1. For the post hoc PK 
analysis, data were available on 128 of the 134 subjects 
treated with TQ that were included in the PGx analysis.
One of the 199 subjects evaluated was classified as PM 
(0.5  %), 38 were classified as IM (19.1  %) and 160 were 
classified as EM (80.4 %) (Table 2). All three subjects from 
India were EMs. From Peru, there was one PM (0.9 %), 12 
IMs (10.5 %) and 101 EMs (88.6 %), while from Thailand, 
there were 26 IMs (31.7 %) and 56 EMs (68.3 %). There 
was a statistically significant difference (p < 0.001) in the 
frequency of the CYP2D6 IM phenotype between Peru 
(n =  12/114, 10.5  %) and Thailand (n =  26/82, 31.7  %) 
(see Additional file  1), but not between the four treat-
ment arms (TQ high dose  +  CQ, TQ low dose  +  CQ, 
PQ + CQ, CQ only; p = 0.09) (see Additional file 2).
Table 1 Clinical outcome and country by treatment in 199 subjects involved in the CYP2D6 PGx analysis










N, subjects (%) per treatment arm
Clinical outcome
 6 month relapse‑free (n = 126) 18 (53) 17 (49) 32 (86) 26 (93) 23 (74) 10 (29)
 Relapsed (n = 73) 16 (47) 18 (51) 5 (14) 2 (7) 8 (26) 24 (71)
Country
 India (n = 3) 1 (3) 1 (3) 1 (3) 0 (0) 0 (0) 0 (0)
 Peru (n = 114) 20 (59) 21 (60) 19 (51) 16 (57) 18 (58) 20 (59)
 Thailand (n = 82) 13 (38) 13 (37) 17 (46) 12 (43) 13 (42) 14 (41)
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Table 2 Distribution of CYP2D6 genotype, metabolizer phenotype and activity score
a CYP2D6 poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM)













*4/*4 PM 0 1 (0.5) – 1 (0.9) –
*4/*41 IM 0.5 1 (0.5) – 1 (0.9) –
*1/*4 IM 1.0 11 (5.5) – 8 (7.0) 3 (3.7)
*10/*10 IM 1.0 19 (9.5) – – 19 (23.2)
*10/*41 IM 1.0 2 (1) – – 2 (2.4)
*2/*4 IM 1.0 3 (1.5) – 3 (2.6) –
*41/*41 IM 1.0 2 (1) – – 2 (2.4)
*1/*10 EM 1.5 15 (7.5) – – 15 (18.3)
*1/*41 EM 1.5 6 (3) – 3 (2.6) 3 (3.7)
*1/*9 EM 1.5 2 (1) – 2 (1.8) –
*2/*10 EM 1.5 14 (7) – – 14 (17.1)
*2/*41 EM 1.5 4 (2) – – 4 (4.9)
*1/*1 EM 2.0 47 (23.6) – 35 (30.7) 12 (14.6)
*1/*2 EM 2.0 45 (22.6) 3 (100) 40 (35.1) 2 (2.4)
*2/*2 EM 2.0 27 (13.6) – 21 (18.4) 6 (7.3)
12% 0% 55% 33% 17% 50% 75% 40%
N =  58 N =  7 N =  51 N =  18 N =  23 N =  8 N =  28 N =  5
OR=0.46, 95% CI 0.02, 8.87
p−value=0.57
OR=0.51, 95% CI 0, 1.66
p−value=0.79
OR=9.18, 95% CI 1.0, infinity
p−value=0.05





















Fig. 1 Clinical outcome by treatment and CYP2D6 status. Relapse frequency is the percentage (%) of subjects who experienced a relapse, with 
error bars representing the standard error of the mean. Odds ratios (ORs) and 95 % confidence intervals (95 % CI) were from analyses comparing the 
relapse frequency of reduced metabolizers (IMs) with that of extensive metabolizers (EMs) within each treatment group. Exact logistic regression 
was used to derive ORs, except for the TQ high dose arm (TQ 300 mg/TQ 600 mg), in which Fisher’s Exact test was used with a correction of 0.05 to 
each cell as there were no IM subjects who relapsed. One‑sided p values (p) are displayed (see “Methods” section)
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No evidence of association between CYP2D6 IM phe-
notype and increased frequency of clinical relapse of P. 
vivax infection was seen in either of the TQ treatment 
groups using a one-sided test as described in the Meth-
ods (Fig.  1). Relapse frequencies were actually lower in 
IM subjects in both TQ treatment groups, a trend that 
was also observed in the CQ only arm. Notably, all seven 
IM subjects in the TQ high dose (300/600  mg) treat-
ment group remained relapse-free during the 6  months 
of follow-up. By contrast, and in support of previous 
findings [5, 7], the relapse frequency was higher in PQ-
treated subjects who were IM (50 %) than in EM subjects 
(17 %), p = 0.05, odds ratio = 9.18 (95 % CI 1.00, ∞). The 
single PM subject in the clinical study was randomized 
to the CQ arm and relapsed. Comparable results were 
obtained using the CYP2D6 AS approach: no effect was 
observed in the TQ arms or in the CQ arm, whether the 
PM subject was included in the CQ arm or not, while a 
non-significant trend for lower AS scores in subjects who 
relapsed was observed in the PQ arm (p = 0.06).
CYP2D6 phenotype had no significant effect on 
TQ AUC in either the TQ high dose (p =  0.72) or TQ 
low dose (p  =  0.24) groups (Fig.  2). The median AUC 
(interquartile range) in the TQ high dose group was 
125.26 μg.h/ml (100.34–179.65 μg.h/ml) in EM subjects 
and 119.52  μg.h/ml (93.17–136.67  μg.h/ml) in IM sub-
jects. In the TQ low dose group, the median AUC (inter-
quartile range) was 24.88 μg.h/ml (17.86–36.50 μg.h/ml) 
in EM subjects and 34.92 μg.h/ml (16.89–37.04 μg.h/ml) 
in IM subjects.
In vitro metabolism of TQ studied in CYP Super-
somes™ and human hepatocytes indicated minimal 
metabolism of TQ. A summary of the structural infor-
mation for the drug-related components of TQ are 
shown in Fig.  3, however, it should be noted that the 
majority of these components were observed in both 
sample and control incubations at comparable levels 
and are therefore likely to be due to degradation of TQ, 
and not true metabolites. In all incubations (includ-
ing controls), the prominent component was TQ, with 

















Fig. 2 Box whisker plot of TQ AUC by CYP2D6 status. The box whisker plots are displayed separately for the TQ high dose arm (TQ 300 mg/TQ 600 mg) 
and TQ low dose (TQ 50 mg/TQ 100 mg) arms, respectively. The median AUC is represented by the thick horizontal line, while the lower and upper 
box edges (‘hinges’) represent the quartiles (the 25th and 75th percentiles). The interquartile range (IQR) is the distance between the first and third 
quartiles. The upper (lower) whisker extends from the upper (lower) hinge to the highest (lowest) value that is within 1.5 *IQR of the hinge
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additional components resulting from O-demethylation, 
O-dearylation, oxidation, and N-acetylation. Following 
120-min incubations of 5 and 10  µM TQ with Super-
somes™ containing overexpressed CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, or CYP3A4, no additional 
drug-related components were detected which were 
not observed in the control incubations, indicating no 
or negligible metabolism of TQ had occurred. Follow-
ing a six-day human hepatocyte relay, a minor compo-
nent, carboxy-TQ, was the only additional TQ-related 
component detected by UPLC-MS. Carboxy-TQ was not 
observed in control incubations, indicating that minimal 
metabolism had occurred even after this long incubation 
period and despite a good metabolic capacity of the prep-
aration (viability of the hepatocytes used ranged from 
91–93 %).
Discussion
PQ has been approved for treating relapsing malaria since 











































































Only carboxy-TQ (circled above) was considered a metabolite; all other drug-related components were detected in both sample and control incubations.
(8.7 min; m/z 464.2162)
(3.7 min; m/z 304.1668)
(8.6 min; m/z 479.1776)
(4.1 min; m/z 334.1779)
(6.8 min; m/z 480.2114) (10.2 min; m/z 492.2112)
(10.3 min; m/z 506.2274)
(3.6 min; m/z 304.1678)
Fig. 3 Summary of TQ‑related components detected in incubations of TQ with recombinant human CYP Supersomes. TQ‑related compounds 
detected in 5 and 10 μM incubations of TQ with recombinant human CYP enzymes (Supersomes™), hepatocytes and appropriate controls (reten‑
tion time and protonated molecular ion observed by UPLC‑MS in parenthesis). The Carboxy‑TQ derivative observed after prolonged incubation is 
circled
Page 8 of 9St Jean et al. Malar J  (2016) 15:97 
used in areas where P. vivax is endemic [1]. Factors that 
have hampered PQ’s effectiveness in developing coun-
tries include poor compliance, due to a lengthy treatment 
regime (typically 14 days), and concerns around the risk of 
haemolysis in G6PD-deficient individuals. While both PQ 
and TQ have G6PD liability, TQ’s long half-life has ena-
bled a single dose regime in current clinical trials, which 
could be expected to result in good patient compliance.
As highlighted recently, a potential CYP2D6 PGx lia-
bility for 8-AQs would represent a significant obstacle 
to large-scale prophylaxis and eradication campaigns 
for P. vivax [8]. Here, a retrospective PGx analysis was 
performed on the effect of inferred CYP2D6 phenotype 
on TQ PK and TQ relapse efficacy in participants from 
TAF112582, a published randomized phase 2b clinical 
trial [2]. Given the known global variation in allele fre-
quencies, the difference in CYP2D6 metabolizer pheno-
type observed between subjects from Thailand and Peru 
was as expected and driven primarily by CYP2D6*10, a 
functionally-deficient allele common in Asian countries 
[17]. These results demonstrate that TQ efficacy is not 
diminished in P. vivax-infected individuals who have 
reduced CYP2D6 metabolism nor is TQ PK affected by 
CYP2D6, a finding that is at odds with previously pub-
lished research in mice [8, 9]. However, these data sup-
port the growing body of evidence implicating reduced 
CYP2D6 metabolism in PQ failure [3–7].
In contrast to PQ [4], metabolites of TQ, in particular 
those potentially resulting from CYP2D6 metabolism, are 
considered less likely to influence the efficacy of this drug, 
which agrees with findings from the PGx and PK analyses 
conducted in this report. At present, the mechanism of 
action for TQ is not known as few metabolites have been 
observed in subjects dosed with TQ. Further support for 
a differential effect of CYP2D6 on TQ and PQ metabo-
lism comes from various in  vitro human liver drug 
metabolism investigations (including those described 
within this publication), all of which have demonstrated 
minimal hepatic metabolic turnover of TQ. This would 
suggest that unlike PQ, metabolism of TQ may not be 
an important factor in vivo for efficacy against P. vivax. 
Unpublished analyses for TQ metabolites in plasma (and 
blood) collected from healthy female volunteers dosed 
orally with TQ (up to 300 mg) for 3 days are consistent 
with in  vitro findings reported here. The only circulat-
ing oxidative metabolite of TQ observed in 0–144-hour 
pools was carboxy-TQ, which was estimated by ultravio-
let spectroscopy and mass spectrometry to be at very low 
levels compared to unchanged TQ (unpublished data on 
file within DMPK Department, GSK).
Taken together, the in vivo and in vitro data presented 
here provide evidence that TQ efficacy against P. vivax 
might not be reliant on CYP2D6 metabolism to the same 
extent as PQ. As indicated previously, the translation of 
genotype information into metabolizer phenotype is 
challenging and small sample size limits conclusions that 
can be drawn from the PGx component of this study, 
including whether TQ efficacy is different in CYP2D6 
PM and IMs. Therefore, the current hypothesis and any 
potential CYP2D6 effects on TQ and PQ efficacy will be 
further evaluated in the ongoing phase 3 programmes 
(TAF112582 Part 2 and TAF116564).
Conclusion
Converging evidence suggests that TQ P. vivax radical 
cure efficacy in humans is not impacted in individuals 
with decreased CYP2D6 metabolism to the same extent 
as PQ.
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